The clinical heterogeneity in cystic fibrosis (CF) is only partly explained by mutations in the CFTR gene. Most CF patients have evidence of liver dysfunction and focal biliary cirrhosis (fibrosis), and a subset of these patients (5-7%) progresses to severe liver disease (CFLD), as defined by portal hypertension and multilobular cirrhosis. The development of CFLD has no relationship to specific CFTR mutations or other biomarkers, and there is currently no way to identify which CF infants will develop severe liver disease. The central hypothesis of this proposal is that the development of CFLD reflects the influence of non-CFTR """"""""modifier"""""""" alleles (genes). This project is designed to identify associations between non-CFTR genes and CFLD, and test the biological effect of selected alleles on hepatic fibrosis in transgenic murine models. We hypothesize that polymorphisms in multiple genes, each with a conceptual or mechanistic link to liver disease, increase the risk for developing end-stage CF liver disease, and that interactions among these risk factors will define the pathophysiology of this disorder. To achieve our goals, we will study 400 CF patients with well-documented severe liver disease and portal hypertension, and 400 gender and genotype-matched CF patients > age 15 years who have no evidence of CFLD. We propose to identify heritable risk factors for the development of CFLD by evaluation of functional sequence variants within, and single nucleotide polymorphisms associated with, multiple genes associated with CFLD pathogenesis. To test (""""""""validate"""""""") the biological effects (impact) of selected genetic alleles on liver fibrosis, we will develop transgenic mice homozygous for deltaF508, who are also expressing an additional candidate gene modifier allele. Better definition of the complex genotypes that increase risk for severe liver disease in CF will allow early identification of CF infants predisposed to develop end-stage liver disease, and thereby allow testing of currently available therapies. Better understanding of the pathobiology of hepatic fibrosis in CF will identify novel targets to prevent (or reduce) the development of CFLD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK066368-04
Application #
7185811
Study Section
Special Emphasis Panel (ZRG1-SSS-G (50))
Program Officer
Mckeon, Catherine T
Project Start
2004-03-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
4
Fiscal Year
2007
Total Cost
$627,428
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Bustamante-Marin, Ximena M; Ostrowski, Lawrence E (2017) Cilia and Mucociliary Clearance. Cold Spring Harb Perspect Biol 9:
Stonebraker, Jaclyn R; Ooi, Chee Y; Pace, Rhonda G et al. (2016) Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 14:1207-1215.e3
Blackman, Scott M; Commander, Clayton W; Watson, Christopher et al. (2013) Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 62:3627-35
Sun, Lei; Rommens, Johanna M; Corvol, Harriet et al. (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44:562-9
Wright, Fred A; Strug, Lisa J; Doshi, Vishal K et al. (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539-46
Li, W; Sun, L; Corey, M et al. (2011) Understanding the population structure of North American patients with cystic fibrosis. Clin Genet 79:136-46
Blackman, S M; Hsu, S; Ritter, S E et al. (2009) A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 52:1858-65
Bartlett, Jaclyn R; Friedman, Kenneth J; Ling, Simon C et al. (2009) Genetic modifiers of liver disease in cystic fibrosis. JAMA 302:1076-83
Li, Chun; Li, Mingyao; Lange, Ethan M et al. (2008) Prioritized subset analysis: improving power in genome-wide association studies. Hum Hered 65:129-41
Hillian, A D; Londono, D; Dunn, J M et al. (2008) Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 9:501-8

Showing the most recent 10 out of 11 publications